一名接受伊布替尼治疗的慢性淋巴细胞白血病患者出现明显的骨髓瘤。
Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy.
作者信息
Al-Katib Ayad M, Gaith Hussein, Sano Dahlia, Al-Katib Sayf, Bonnett Michelle, Kafri Zyad
机构信息
Lymphoma Research Laboratory Department of Internal Medicine Wayne State University School of Medicine (WSU SOM) Detroit MI USA.
Department of Oncology Karmanos Cancer Institute WSU SOM Detroit MI USA.
出版信息
Clin Case Rep. 2020 Jul 15;8(9):1797-1801. doi: 10.1002/ccr3.3019. eCollection 2020 Sep.
Ibrutinib is approved for chronic lymphocytic leukemia (CLL). However, its role in the treatment of multiple myeloma (MM) is not clear and is under investigation. We report a case of CLL that developed MM while on therapy with ibrutinib indicating that this drug may not be active against MM.
伊布替尼已被批准用于治疗慢性淋巴细胞白血病（CLL）。然而，其在多发性骨髓瘤（MM）治疗中的作用尚不清楚，仍在研究中。我们报告了1例在接受伊布替尼治疗期间发生MM的CLL病例，表明该药物可能对MM无效。
Zotero 插件